Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

Fig. 3

BTLA-HVEM cis and trans signaling in different settings. A In resting T cells, BTLA inhibitory signaling plays a predominant role in cis interactions, impeding HVEM-mediated activation. B Upon activation, BTLA-HVEM cis complex is disrupted thus allowing trans interactions between BTLA and HVEM-expressing cells. C In the context of cancer, enhanced BTLA expression on tumor-infiltrating lymphocytes increase trans interaction and leads to the inhibition of T cell-mediated antitumor responses

Back to article page

Molecular Cancer

ISSN: 1476-4598